Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States.
作者信息
Patell Rushad, Midha Shonali, Kimani Stephen, Martin Richard, Neparidze Natalia, Jaglal Michael, Freed Jason, Key Nigel S
机构信息
Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, Florida, United States.
出版信息
Thromb Haemost. 2020 Dec;120(12):1725-1732. doi: 10.1055/s-0040-1715837. Epub 2020 Aug 22.
Abstract
摘要
相似文献
1
Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States.
Thromb Haemost. 2020 Dec;120(12):1725-1732. doi: 10.1055/s-0040-1715837. Epub 2020 Aug 22.
2
COVID-19 update: Covid-19-associated coagulopathy.
J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3.
3
Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.
Pharmacotherapy. 2020 Nov;40(11):1130-1151. doi: 10.1002/phar.2465. Epub 2020 Nov 3.
4
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
5
A Ghana-UK haematology "heparin" partnership.
Br J Haematol. 2020 Nov;191(3):e96-e97. doi: 10.1111/bjh.17048. Epub 2020 Aug 15.
6
Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?
J Thromb Haemost. 2020 Nov;18(11):3106-3108. doi: 10.1111/jth.15021.
7
Transfusion requirements in patients with COVID-19.
Eur J Haematol. 2021 Jan;106(1):132-134. doi: 10.1111/ejh.13521. Epub 2020 Oct 9.
8
COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year.
Lancet Haematol. 2021 Jul;8(7):e524-e533. doi: 10.1016/S2352-3026(21)00105-8. Epub 2021 Apr 27.
9
Coagulation abnormalities & thromboprophylaxis in COVID-19.
Indian J Med Res. 2021;153(5&6):606-618. doi: 10.4103/ijmr.IJMR_3841_20.
10
Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?
J Thromb Haemost. 2024 Jun;22(6):1541-1549. doi: 10.1016/j.jtha.2024.02.013. Epub 2024 Feb 29.
引用本文的文献
1
National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19.
Iran J Pharm Res. 2022 Mar 30;21(1):e123947. doi: 10.5812/ijpr.123947. eCollection 2022 Dec.
2
Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing.
Res Pract Thromb Haemost. 2022 Apr 5;6(3):e12683. doi: 10.1002/rth2.12683. eCollection 2022 Mar.
3
Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study.
JMIR Med Inform. 2021 Nov 18;9(11):e30743. doi: 10.2196/30743.
4
Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform.
JCO Oncol Pract. 2022 Jan;18(1):e36-e46. doi: 10.1200/OP.20.00960. Epub 2021 Jul 9.
5
The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper.
Thromb Haemost. 2021 Aug;121(8):992-1007. doi: 10.1055/a-1535-8807. Epub 2021 Jul 20.
6
Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis.
Thromb Haemost. 2021 Jan;121(1):76-85. doi: 10.1055/s-0040-1721664. Epub 2020 Dec 30.
7
Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.
Physiol Rev. 2021 Apr 1;101(2):545-567. doi: 10.1152/physrev.00035.2020. Epub 2020 Oct 30.
本文引用的文献
1
Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology.
Rev Esp Cardiol (Engl Ed). 2020 Sep;73(9):749-757. doi: 10.1016/j.rec.2020.04.025. Epub 2020 Jun 19.
2
Emergence of institutional antithrombotic protocols for coronavirus 2019.
Res Pract Thromb Haemost. 2020 Jun 12;4(4):510-517. doi: 10.1002/rth2.12358. eCollection 2020 May.
3
Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy-Either, Neither, or Both.
Semin Thromb Hemost. 2020 Oct;46(7):781-784. doi: 10.1055/s-0040-1712156. Epub 2020 Jun 8.
4
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Thromb Haemost. 2020 Jul;120(7):1004-1024. doi: 10.1055/s-0040-1713152. Epub 2020 May 30.
5
Coagulation abnormalities and thrombosis in patients with COVID-19.
Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.
6
Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels.
Thromb Res. 2020 Aug;192:23-26. doi: 10.1016/j.thromres.2020.05.018. Epub 2020 May 13.
7
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.
Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.
8
COVID-19: towards understanding of pathogenesis.
Cell Res. 2020 May;30(5):367-369. doi: 10.1038/s41422-020-0327-4.
9
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.
N Engl J Med. 2020 May 14;382(20):e60. doi: 10.1056/NEJMc2009787. Epub 2020 Apr 28.
10
COVID-19 and its implications for thrombosis and anticoagulation.
Blood. 2020 Jun 4;135(23):2033-2040. doi: 10.1182/blood.2020006000.
Zotero 插件